Acorda Therapeutics (ACOR) Appoints Andrew Hindman As Chief Business Development Officer
5/14/2014 7:19:23 AM
Acorda Therapeutics, Inc. (Nasdaq:ACOR) has appointed Andrew Hindman as Chief Business Development Officer.
“Business development is a key to Acorda’s growth strategy, and I am delighted that Andrew will lead our efforts to acquire new assets that add to our promising pipeline. Andrew is a highly talented, experienced business leader with an outstanding track record of identifying and completing value-creating strategic transactions,” said Ron Cohen, M.D., Acorda’s President and CEO.
Help employers find you! Check out all the jobs and post your resume.
comments powered by